Status and phase
Conditions
Treatments
About
This study will analyze and evaluate the following items:
Subjects from 18 to 75 years of age who are diagnosed with a solid tumor including pancreatic cancer, lung cancer, breast cancer, ovarian cancer and colon cancer, and for whom standard treatments are not effective, may be eligible for this study. Participants undergo the following procedures:
Peripheral blood will be collected from a vein of arm. Peripheral blood mononuclear cells(PBMC) will be isolated and purified for NK manufacturing. After 14~21 days cultivation, activated NK will be harvested and formulated for clinical administration.
Subjects will receive NK cell treatment by intravenous infusion. The frequency is once every 3 or 4 weeks for the first 3 months. Participants who respond well after 3 months may be eligible to continue NK cell therapy; and those not may receive NK therapy combined with chemotherapy and/or targeted drugs, or chemotherapy/targeted drugs alone.
Evaluations during therapy including:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age from 18 to 75 years (including boundary values);
Diagnosed with histologically and cellularly confirmed cancer of lung, breast, pancreas, ovary, or colon;
At least 8 weeks since any prior systemic therapy to treat the underlying malignancy (standard or investigational);
Life expectancy > 6 months, and performance status(KPS)> 60 points;
Organ functions meet the following criteria:
No severe infections.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
200 participants in 1 patient group
Loading...
Central trial contact
Zhiguo Chen, PhD; Yu Zhao, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal